“…The two lead compounds of this series are latrunculin A ( 1 ) and latrunculin B ( 2 ), originally isolated from the Red Sea sponge Negombata magnifica (old genus designation Latrunculia ). , Their basic structural motif consists of a macrolide 1,3 fused to a tetrahydropyran containing a 2-thiazolidinone side chain. Compound 1 also shares a carbon skeleton with the anticancer active epothilone A, obtained from cultures of the terrestrial myxobacterium Sorangium cellulosum . , The sustained attention given to the latrunculins can be attributed to three factors: a unique mixed biogenesis from PKS/NRPS, , a Abbreviations: DFT, density functional theory; PKS/NRPS, polyketide synthase/nonribosomal peptide synthetase; MAE, mean absolute error; colon 38, murine colon adenocarcinoma; L1210, murine lymphocytic leukemia; CFU-GM, murine bone marrow; HCT-116, human colorectal carcinoma; MDA-MB-435, human breast cancer; SRB, sulforhodamine B; A10, rat smooth muscle; DTP, developmental therapeutics program. their potent actin inhibition properties, , and their potent cytotoxicity against cancer cell lines . In comparison to the many other common natural product actin inhibitors latrunculin A is the most widely used small molecule molecular probe.…”